MD Anderson Cancer Center and AbbVie form immuno-oncology collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD ANDERSON CANCER CENTER and AbbVie formed a three-year collaboration to perform preclinical and clinical studies evaluating immuno-oncology therapies. AbbVie and MD Anderson will each assign two scientists to a joint scientific committee, which will decide on which projects to pursue. The collaboration will begin with projects driven by AbbVie Biotherapeutics. Future projects will draw...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login